BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30026158)

  • 1. Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.
    Saeger W; Müller M; Buslei R; Flitsch J; Fahlbusch R; Buchfelder M; Knappe UJ; Crock PA; Lüdecke DK
    World Neurosurg; 2018 Nov; 119():e118-e124. PubMed ID: 30026158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
    Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
    Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
    Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
    Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
    Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
    Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
    Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
    Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
    de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
    Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence in pituitary adenomas in childhood and adolescence.
    Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
    J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
    Miyagami M; Nakamura S
    No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
    Hentschel SJ; McCutcheon lE; Moore W; Durity FA
    Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
    Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
    Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
    Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
    Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
    Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
    J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
    Hirohata T; Ishii Y; Matsuno A
    Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
    Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
    J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
    Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
    Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas.
    Fukui S; Otani N; Nawashiro H; Yano A; Nomura N; Miyazawa T; Ohnuki A; Tsuzuki N; Katoh H; Ishihara S; Shima K
    Brain Tumor Pathol; 2002; 19(1):23-9. PubMed ID: 12455885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
    Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.
    Miermeister CP; Petersenn S; Buchfelder M; Fahlbusch R; Lüdecke DK; Hölsken A; Bergmann M; Knappe HU; Hans VH; Flitsch J; Saeger W; Buslei R
    Acta Neuropathol Commun; 2015 Aug; 3():50. PubMed ID: 26285571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NRP-1 expression is strongly associated with the progression of pituitary adenomas.
    Lee SW; Lee JE; Yoo CY; Ko MS; Park CS; Yang SH
    Oncol Rep; 2014 Oct; 32(4):1537-42. PubMed ID: 25109698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.